283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Shubham Pant; Amishi Shah; Pavlos Msaouel; Matthew Campbell; Shi-Ming Tu; Jianjun Gao; George Blumenschein; Frank Mott; Xiuning Le; Mehmet Altan; Funda Meric-Bernstam; Timothy Yap; Vivek Subbiah; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael Chisamore; Alexander Stevenson; Nizar Tannir

doi:10.1136/jitc-2020-SITC2020.0283

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Regular and young investigator award abstracts

Clinical trials completed

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password